EP3464608A4 - Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci - Google Patents

Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci Download PDF

Info

Publication number
EP3464608A4
EP3464608A4 EP17807601.4A EP17807601A EP3464608A4 EP 3464608 A4 EP3464608 A4 EP 3464608A4 EP 17807601 A EP17807601 A EP 17807601A EP 3464608 A4 EP3464608 A4 EP 3464608A4
Authority
EP
European Patent Office
Prior art keywords
compositions
same
methods involving
therapeutic recombinant
klotho proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17807601.4A
Other languages
German (de)
English (en)
Other versions
EP3464608A1 (fr
Inventor
Joseph F. Tarsio
Dinesh RATURI
James R. PLANTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klotho Therapeutics Inc
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of EP3464608A1 publication Critical patent/EP3464608A1/fr
Publication of EP3464608A4 publication Critical patent/EP3464608A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP17807601.4A 2016-06-02 2017-06-02 Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci Pending EP3464608A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662344743P 2016-06-02 2016-06-02
US201662375046P 2016-08-15 2016-08-15
US201662401600P 2016-09-29 2016-09-29
US201662425237P 2016-11-22 2016-11-22
US201762456318P 2017-02-08 2017-02-08
PCT/US2017/035755 WO2017210607A1 (fr) 2016-06-02 2017-06-02 Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci

Publications (2)

Publication Number Publication Date
EP3464608A1 EP3464608A1 (fr) 2019-04-10
EP3464608A4 true EP3464608A4 (fr) 2020-01-29

Family

ID=60477890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17807601.4A Pending EP3464608A4 (fr) 2016-06-02 2017-06-02 Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci

Country Status (9)

Country Link
EP (1) EP3464608A4 (fr)
JP (3) JP2019526272A (fr)
KR (2) KR102570250B1 (fr)
CN (2) CN116478907A (fr)
AU (1) AU2017272349B2 (fr)
BR (1) BR112018073909A2 (fr)
CA (1) CA3025461A1 (fr)
MX (2) MX2018014753A (fr)
WO (1) WO2017210607A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996555A (zh) * 2016-11-22 2019-07-09 克洛索治疗有限公司 新颖重组klotho蛋白及其组合物和方法
CN108333355B (zh) * 2018-02-01 2020-05-26 黄曙 Klotho蛋白在制备诊断胃肠道间质瘤危险度的试剂中的用途
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
WO2020106997A1 (fr) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Méthodes et matériels de réduction d'un muscle strié et d'un déclin cognitif liés à l'âge
WO2020160617A1 (fr) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd Composition de modulation de l'expression et de la distribution de protéines membranaires et son procédé d'utilisation
RU2712770C1 (ru) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Способ ингибирования роста опухолевых клеток
IT201900007446A1 (it) 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115515645A (zh) * 2019-12-05 2022-12-23 哈佛学院董事及会员团体 治疗骨关节炎的方法
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112195165A (zh) * 2020-10-15 2021-01-08 广东药科大学 一种抗衰老分泌型Klotho蛋白及其编码基因、重组表达载体与应用
CN114487218B (zh) * 2020-10-23 2023-11-14 北京红惠新医药科技有限公司 β-烟酰胺单核苷酸的分析方法
CN112915193B (zh) * 2021-03-05 2022-09-13 南方医科大学南方医院 Kp-1在制备治疗慢性肺病的药物中的用途
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113215199A (zh) * 2021-04-29 2021-08-06 广州博识生物科技有限公司 一种Klotho+/-基因缺失斑马鱼
CN117529331A (zh) * 2021-05-21 2024-02-06 巴塞罗那自治大学 用于治疗骨病症的Klotho分泌型剪接变体
CN113409306A (zh) * 2021-07-15 2021-09-17 推想医疗科技股份有限公司 一种检测装置、训练方法、训练装置、设备和介质
WO2023172444A2 (fr) * 2022-03-08 2023-09-14 Mayo Foundation For Medical Education And Research Agents sénothérapeutiques et polypeptides alpha-klotho
US20250296972A1 (en) * 2022-05-08 2025-09-25 Ichilov Tech Ltd. Klotho derivatives with modified structure
EP4626463A1 (fr) * 2022-12-02 2025-10-08 Universitat Autònoma de Barcelona Variant d'épissage sécrété de klotho pour le traitement de troubles musculaires
CN116173077B (zh) * 2023-03-21 2025-07-25 哈尔滨医科大学 动物双歧杆菌的应用
EP4434534A1 (fr) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Arnm de klotho
CN117679530B (zh) * 2023-11-13 2025-07-18 中国人民解放军陆军军医大学第二附属医院 一种GP-pKlotho纳米药物及其制备方法和应用
EP4566618A1 (fr) 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Acide nucléique codant pour klotho pour utilisation dans des procédés thérapeutiques et non thérapeutiques pour réduire le poids corporel
WO2025109173A1 (fr) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Acide nucléique codant pour klotho destiné à être utilisé dans des méthodes thérapeutiques et non thérapeutiques pour réduire le poids corporel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
WO2001020031A2 (fr) * 1999-09-10 2001-03-22 Kyowa Hakko Kogyo Co Ltd Polymorphismes dans un gene klotho

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072607A (ja) * 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd 新規血管内皮機能改善法
US7332303B2 (en) * 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP2006240990A (ja) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
CN102861343A (zh) * 2012-10-17 2013-01-09 南方医科大学 分泌型Klotho在制备治疗慢性肾脏病的药物中的应用
US20160120959A1 (en) 2013-03-14 2016-05-05 The Board Of Regents Of The University Of Oklahoma Use of Klotho Nucleic Acids or Proteins for Treatment of Diabetes and Diabetes-Related Conditions
LT3132247T (lt) * 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
WO2001020031A2 (fr) * 1999-09-10 2001-03-22 Kyowa Hakko Kogyo Co Ltd Polymorphismes dans un gene klotho

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARKING DAN E ET AL: "Association of human aging with a functional variant of klotho", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 99, no. 2, 22 January 2002 (2002-01-22), pages 856 - 861, XP002572557, ISSN: 0027-8424, [retrieved on 20020115], DOI: 10.1073/PNAS.022484299 *
KATO YUKINARI ET AL: "Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 267, no. 2, 19 January 2000 (2000-01-19), pages 597 - 602, XP002572556, ISSN: 0006-291X, DOI: 10.1006/BBRC.1999.2009 *
See also references of WO2017210607A1 *
TOHYAMA OSAMU ET AL: "Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 11, 12 March 2004 (2004-03-12), pages 9777 - 9784, XP002523385, ISSN: 0021-9258, DOI: 10.1074/JBC.M312392200 *
YAMAZAKI Y ET AL: "Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 398, no. 3, 30 July 2010 (2010-07-30), pages 513 - 518, XP027185031, ISSN: 0006-291X, [retrieved on 20100701], DOI: 10.1016/J.BBRC.2010.06.110 *

Also Published As

Publication number Publication date
EP3464608A1 (fr) 2019-04-10
KR20230125857A (ko) 2023-08-29
AU2017272349B2 (en) 2022-12-01
JP2023123565A (ja) 2023-09-05
KR102570250B1 (ko) 2023-08-29
KR20190015711A (ko) 2019-02-14
CN109219663A (zh) 2019-01-15
CA3025461A1 (fr) 2017-12-07
MX2018014753A (es) 2019-06-17
KR102840156B1 (ko) 2025-07-31
AU2017272349A1 (en) 2018-11-22
BR112018073909A2 (pt) 2019-02-26
JP2019526272A (ja) 2019-09-19
CN116478907A (zh) 2023-07-25
WO2017210607A1 (fr) 2017-12-07
MX2023008626A (es) 2023-08-08
JP2025090742A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
IL276464A (en) Methods and preparations for administering therapeutic protein
IL265489B (en) Recombinant binding proteins and their uses
ZA201802003B (en) Dual function proteins and pharmaceutical composition comprising same
EP3235830A4 (fr) Complexe protéine-interleukine 15 et utilisation associée
EP3638290A4 (fr) Conjugués peptidiques de retour (homing) rénal et leurs procédés d'utilisation
ZA202101250B (en) Novel crispr-associated protein and use thereof
EP3290441A4 (fr) PROTÉINE DE LIAISON À RGMa ET SON UTILISATION
EP3285805A4 (fr) Anticorps thérapeutiques et utilisations de ceux-ci
EP3393586A4 (fr) Thérapie d'association par inhibiteur de bromodomaine et de protéine extra-terminale
EP3642219A4 (fr) Compositions peptidiques et procédés associés
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
EP3377085A4 (fr) Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
ZA202100092B (en) Modified cas9 protein and use thereof
EP3302530A4 (fr) Agents thérapeutiques à base de cdh26 et leur utilisation
EP3270985A4 (fr) Compositions de polypeptide et leurs procédés d'utilisation
EP3399990A4 (fr) Compositions thérapeutiques contenant des peptides et leurs utilisations
EP3256578B8 (fr) Polypeptides pour l'ingénierie de protéines intégrases chimériques et leur utilisation en thérapie génique
EP3268042A4 (fr) Composition contenant un polypeptide anti-tnf-alpha et utilisation
EP3866830A4 (fr) Procédés et compositions de polypeptide de vaccin
EP3325499A4 (fr) Nouveau peptide et utilisation associée
EP3562839A4 (fr) Polypeptides recombinants, compositions et procédés associés
EP3452078A4 (fr) Composition isotopiquement modifiée et ses utilisations thérapeutiques
HK40033822A (en) Therapeutic protein compositions and methods of making and using the same
HK40030279A (en) Synthetic proteins and therapeutic uses thereof
HK40052531A (en) Immunogenic proteins and compositions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101ALI20191220BHEP

Ipc: A61K 38/22 20060101ALI20191220BHEP

Ipc: C12P 21/06 20060101AFI20191220BHEP

Ipc: A61K 38/17 20060101ALI20191220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241007